Director – Field Operations & Effectiveness
Rhythm Pharmaceuticals
Director – Field Operations & Effectiveness
Rhythm Pharmaceuticals
Commercializes MC4R-targeted therapies for rare obesity
Commercializes MC4R-targeted therapies for rare obesity
Rhythm Pharmaceuticals focuses on developing therapies for rare neuroendocrine genetic obesity disorders, led by IMCIVREE (setmelanotide). IMCIVREE is an MC4R agonist that restores signaling in the MC4R pathway to curb hunger and regulate energy use; it is FDA, EC, and MHRA approved for Bardet-Biedl syndrome and certain POMC/PCSK1/LEPR deficiencies in patients aged 2 and older, with revenue from global sales. The company differentiates itself by pursuing precision medicine for MC4R pathway diseases and advancing additional MC4R programs like bivamelagon and RM-718. Rhythm’s goal is to broaden access to MC4R-targeted therapies for rare patient populations and grow its pipeline toward sustainable commercialization.
Explore more opportunities at Rhythm Pharmaceuticals